

Arkema Oddo MidCap Forum


Lyon – January, 9th and 10th, 2014


Sophie FouillatVP Investor Relations



Arkema 2012 profile

- Sales of €6.4 bn
- EBITDA of €996 m
- Industry-leading margin at 15.6%
- 13,925 employees in 40 countries
- Capex of €438 m
- R&D at 2.3% of sales
- Strong balance sheet







Among top players on 90% of our sales

POSITION		MARKET SIZE (mT)	MAIN PLAYERS	% GROUP SALES
#1	Specialty polyamides	0.2	EvonikEms	14%
#1	PVDF		• Solvay	
#2	Organic peroxides	0.2	Akzo NobelUnited Initiators	4%
#1	Thiochemicals	0.7	Chevron Phillips	9%
#1/2	Fluorogases	1.6	DupontHoneywell	10%
#2	PMMA	1.6	 Evonik Mitsubishi Chemical	10%
#3	Hydrogen peroxide	3.2	SolvayEvonik	3%
#3	Acrylic monomers	4.2	BASFDowNippon Shokubai	13%
#3	Specialty coatings	4.0	BASFDow	21%

As a comparison, a market like PVC is ~40mt











Sales breakdown by business




Diversified end markets









^{*} Akzo Nobel, BASF, Clariant, Lanxess, Solvay ** Dow, Celanese, Chemtura





300

Solid balance sheet and financing


Shareholders' equity	€ 2.3 bn	
Net debt	€ 900 m	
Gearing	39 %	
Net debt / EBITDA	0.9x	

Figures at 31st December 2012


Rating

Standards & Poor's BBB Stable outlook Moody's Baa2 Stable outlook

€1.9bn financing resources (€m)



Average maturity > 4 years (€m)







Clear strategic roadmap

We Become a world leader in specialty chemicals and advanced materials and advanced materials are special to the special to

- Deliver profitable growth and solid cash flow
- Accelerate development of High Performance Materials
- Intensify our presence in high growth countries (China, India, Brazil, Middle East)
- Increase downstream integration in acrylics
- Secure access to strategic raw materials
- Reinforce our operational excellence





2016 financial targets

€8bn Sales

16 % **EBITDA** margin

< 40 % Gearing





2016 targets by segment







High Performance Materials

38% of total sales

18% EBITDA margin

Industrial Specialties

30% of total sales


17% EBITDA margin













Coating Solutions

32% of total sales


15% EBITDA margin





Development in high growth countries

Sales by region (€bn)





Industrial projects to support organic growth

2012 2013 2014



- 2EHA (Acrylic derivates) (United States)
- PVDF expansion (China)
- HFC125 expansion (China)
- ADAME (Acrylic derivate) (France)



- Acrylic acid and esters (United States)
- Superabsorbents*
 (Acrylic derivates)
 (France)
- Coating resins
 (Acrylic derivates)
 (China)
- Hipro expansion (Specialty Polyamides) (China)
- Lacq (Thiochemicals) (France)




- Thiochemical platform (Malaysia)
- Several other projects under consideration

- 2/3 of capex already identify to support planned organic growth
- Strong emphasize on acrylic value chain, Specialty Polyamides and Thiochemicals




Contribution of organic growth projects to EBITDA







A rich pipeline of R&D projects





Cash allocation over 2013 - 2016






Main objectives 2020

Sales (€bn)

EBITDA and EBITDA margin (%)



Gearing < **40**%



Dividend increase reflects strong confidence in Arkema's potential



- Payout: 25% of adjusted net income
- 2.3% dividend yield (based on share price at year end)
- Arkema confirms its target to reach a 30% payout ratio on adjusted net income



Disclaimer

The information disclosed in this document may contain forward-looking statements with respect to the financial condition, results of operations, business and strategy of Arkema. Such statements are based on management's current views and assumptions that could ultimately prove inaccurate and are subject to risk factors such as among others, changes in raw material prices, currency fluctuations, implementation pace of cost-reduction projects and changes in general economic and business conditions.

Arkema does not assume any liability to update such forward-looking statements whether as a result of any new information or any unexpected event or otherwise. Further information on factors which could affect Arkema's financial results is provided in the documents filed with the French Autorité des Marchés Financiers.

Financial information for 2013, 2012, 2011, 2010, 2009, 2008, 2007, 2006 and 2005 is extracted from the consolidated financial statements of Arkema. Quarterly financial information is not audited.

The business segment information is presented in accordance with Arkema's internal reporting system used by the management.

The definition of the main performance indicators used can be found in the reference document filed with the French Autorité des Marchés Financiers and available on www.finance.arkema.com

